Soleno Therapeutics, a California-based clinical-stage biopharmaceutical company, is dedicated to advancing novel therapeutics for the treatment of rare diseases. Its leading candidate, Diazoxide Choline Extended-Release tablets, is currently undergoing Phase III clinical trials for the treatment of Prader-Willi Syndrome. This once-daily oral tablet has shown immense potential in combating the rare genetic disorder that causes developmental issues, obesity, and behavioral problems. The company, formerly known as Capnia, underwent a name change in May 2017 and has been operating since its inception in 1999. With its focus on rare diseases, Soleno Therapeutics is poised to make significant strides in the pharmaceutical industry, and its clinical trials for Diazoxide Choline Extended-Release tablets are being closely watched by investors and medical professionals alike.
Soleno Therapeutics, Inc.'s ticker is SLNO
The company's shares trade on the NASDAQ stock exchange
They are based in Redwood City, California
There are 1-10 employees working at Soleno Therapeutics, Inc.
It is https://soleno.life/
Soleno Therapeutics, Inc. is in the Healthcare sector
Soleno Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Soleno Therapeutics, Inc.'s industry peers: